Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Carmen Fotino, Camillo Ricordi, Vincenzo Lauriola, Rodolfo Alejandro, Antonello Pileggi

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

The bone marrow is an invaluable source of adult pluripotent stem cells, as it gives rise to hematopoietic stem cells, endothelial progenitor cells, and mesenchymal cells, amongst others. The use of bone marrow-derived stem cell (BMC) transplantation (BMT) may be of assistance in achieving tissue repair and regeneration, as well as in modulating immune responses in the context of autoimmunity and transplantation. Ongoing clinical trials are evaluating the effects of BMC to preserve functional beta-cell mass in subjects with type 1 and type 2 diabetes, and to favor engraftment and survival of transplanted islets. Additional trials are evaluating the impact of BMT (i.e., mesenchymal stem cells) on the progression of diabetes complications. This article reviews the progress in the field of BMC for the treatment of subjects with insulin-dependent diabetes, and summarizes clinical data of pilot studies performed over the last two decades at our research center by combining allogeneic islet transplantation with donor-specific BMC. Clinical data is summarized from pilot studies performed at our research center over the last two decades.

Original languageEnglish (US)
Pages (from-to)144-157
Number of pages14
JournalThe review of diabetic studies : RDS
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this